Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NHERF1 | O14745 | 3/20 | 0.50 |
| ▸ | PYGL | P06737 | 2/20 | 0.50 |
| ▸ | CFD | P00746 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | BCR | P11274 | 1/20 | 0.45 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554359 | 0.85 | KDM4E (0.60) | PYGLCFDMMP2MMP13SLC6A2 | |
| SCHEMBL8360314 | 0.85 | SMAD3 (0.62) | NHERF1PYGLKDM4EFLT3ABL1 | |
| SCHEMBL1616512 | 0.81 | ALDH1A1 (0.49) | NHERF1CFDMMP2MMP13SLC6A2 | |
| SCHEMBL22526431 | 0.81 | CFD (0.44) | NHERF1PYGLCFDMMP2MMP13 | |
| SCHEMBL1616735 | 0.80 | CFD (0.44) | NHERF1PYGLCFDMMP2MMP13 | |
| SCHEMBL3608666 | 0.77 | HRH4 (0.56) | CFDMMP2MMP13SLC6A2SLC6A4 | |
| SCHEMBL3282981 | 0.77 | FLT3 (0.73) | FLT3ABL1PDGFRBKITBCR | |
| SCHEMBL1651087 | 0.77 | MMP2 (0.66) | CFDMMP2MMP13KDM4EFLT3 | |
| SCHEMBL13174359 | 0.77 | KDM4E (0.72) | MMP2MMP13SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5795136 | 0.76 | KDM4E (0.48) | NHERF1PYGLMMP2MMP13KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871794-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140051700-A1 | Small-molecule agonists for type-2 orexin receptor | UNIVERSITY OF TEXAS, BOARD OF REGENTS | 2014-02-20 | — | — | US | disclosed |
| US-8258163-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-09-04 | — | — | US | disclosed |
| US-20110178079-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION | 2011-07-21 | — | — | US | disclosed |
| US-20110166181-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-7868028-B2 | Guanidine compounds as anesthetics and for treatment of nervous system disorders | Drasner, Fred (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-17 | — | — | US | disclosed |
| US-20050228022-A1 | blocking voltage-sensitive sodium channels of neurons in a mammal comprising administering 1-benzyl-2-imino-3-(2-hydroxy-3-phenoxypropyl)benzimidazole; analgesics; neuroprotectants; anticonvulsants | TAKTIX CORPORATION (US) | 2005-10-13 | — | — | US | disclosed |
| EP-1551397-A2 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | MediQuest Therapeutics, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2003105779-A2 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | HCRTR2, HCRTR1, OXTR | NHERF1 1638/4885PYGL 932/4885CFD 4295/4885 |
| US-20140051700-A1 | Small-molecule agonists for type-2 orexin receptor | HCRTR2, HCRTR1, OXTR | NHERF1 1638/4885PYGL 932/4885CFD 4295/4885 |
| US-20110166181-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CACNA1E, GRIA4, GRIA3 | NHERF1 483/4885PYGL 2325/4885CFD 4680/4885 |
| US-20050228022-A1 | blocking voltage-sensitive sodium channels of neurons in a mammal comprising administering 1-benzyl-2-imino-3-(2-hydroxy-3-phenoxypropyl)benzimidazole; analgesics; neuroprotectants; anticonvulsants | CACNA1E, CACNA1B, SCN1A | NHERF1 102/4885PYGL 4237/4885CFD 4867/4885 |
| US-20110178079-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | CACNA1E, GRIA4, GRIA3 | NHERF1 511/4885PYGL 2222/4885CFD 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.